Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
GOLDEN, Colo., July 20, 2023 (GLOBE NEWSWIRE) — Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) (“Panacea” or the “Company”), a plant-based natural health and wellness company, today announced it will be presenting its positive findings from open label clinical trial on the efficacy of its CBD/CBG Oral Solution to naturally treat irritable bowel syndrome (IBS) in adults. Led by Dr. Larry Good and Dr. James Baumgartner the study data will be published in the November 2023 issue of the American Journal of Gastroenterology and presented in a poster October 23, 2023, at the American College of Gastroenterology meeting in Vancouver, Canada.
Related news for (PLSH)
- Panacea Life Sciences and Sky Wellness Enter Agreement for Licensing, Marketing, Supply and Development of Sky Wellness CBD Products
- Panacea Life Sciences Holdings, Inc. Completes Acquisition of N7 Enterprises With Eight Natural Health and Wellness Retail and One Distribution Center Locations in the Tampa, Florida area
- Panacea Life Sciences Holdings, Inc. Continues Growth Trajectory with Acquisition of the PÜR LIFE Medical Franchise
- Panacea Life Sciences Holdings, Inc. Celebrates National CBD Day (August 8th) By Shifting To An “Everyday Low Pricing Model” To Meet Customer Needs
- Panacea Life Sciences Holdings, Inc. Continues Pursuit of High Growth Health and Wellness Products with Acquisition of Sierra Sage, LLC and Halucenex from Melodial Global Health (formerly Creso Pharma Limited)